Comprehensive medication guide to Amphetamine/Dextroamphetamine including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Most insured patients pay $0–$30 per month for generic Amphetamine/Dextroamphetamine with a standard copay.
Estimated Cash Pricing
Generic Amphetamine/Dextroamphetamine costs approximately $25–$100 per month without insurance, depending on the formulation and dose.
Medfinder Findability Score
35/100
Summarize with AI
On this page
Amphetamine/Dextroamphetamine is a central nervous system (CNS) stimulant used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children aged 3 and older, as well as narcolepsy. It is sold under brand names including Adderall, Adderall XR, and Mydayis. The medication contains a combination of amphetamine salts—75% dextroamphetamine and 25% levoamphetamine—that work together to improve focus, attention, and impulse control. Generic versions are widely available from manufacturers including Teva, Sandoz, Mallinckrodt, Lannett, Sun Pharma, and Amneal.
Amphetamine/Dextroamphetamine works by increasing the release and blocking the reuptake of dopamine and norepinephrine in the brain. These neurotransmitters play key roles in attention, focus, and impulse control. By boosting their availability, the medication helps reduce ADHD symptoms such as inattention, hyperactivity, and impulsivity. The combination of dextroamphetamine and levoamphetamine provides both rapid and sustained effects. Immediate-release tablets are typically taken 2–3 times daily, while extended-release capsules provide all-day coverage with a single morning dose.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Immediate-release (IR) tablets
5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg, 30mg
Extended-release (XR) capsules
5mg, 10mg, 15mg, 20mg, 25mg, 30mg
Mydayis extended-release capsules
12.5mg, 25mg, 37.5mg, 50mg
Amphetamine/Dextroamphetamine has been in an active shortage since October 2022, when Teva Pharmaceuticals—the largest manufacturer—reported manufacturing delays. Despite the DEA raising production quotas from 21.2 million grams to 26.5 million grams of d-amphetamine in October 2025, supply has not fully recovered. Some strengths and formulations remain intermittently unavailable at pharmacies nationwide. With a findability score of 35 out of 100, this medication is considered difficult to find in stock.
Because Amphetamine/Dextroamphetamine is a Schedule II controlled substance, it requires a prescription from a licensed prescriber. Commonly prescribing specialties include psychiatry, primary care and family medicine, pediatrics, neurology, and internal medicine. Telehealth providers can also prescribe Amphetamine/Dextroamphetamine in many states, though some states have specific rules for prescribing controlled substances via telehealth.
Yes, Amphetamine/Dextroamphetamine is a DEA Schedule II controlled substance, which is the most restrictive category for drugs with accepted medical use. This means it has a high potential for abuse and dependence. Prescriptions cannot be called in to pharmacies in most states—a written or electronic prescription is required. Refills are not allowed; a new prescription must be written each time. Most prescriptions are limited to a 30-day supply.
Serious but rare side effects include cardiovascular events (heart attack, stroke), psychotic symptoms, seizures, and serotonin syndrome when combined with serotonergic drugs. Patients with pre-existing heart conditions should be carefully evaluated before starting this medication.
Know what you need? Skip the search.
Lisdexamfetamine (Vyvanse)
A prodrug of dextroamphetamine with lower abuse potential and once-daily dosing, approved for ADHD and binge eating disorder.
Methylphenidate (Ritalin, Concerta)
A different stimulant class that blocks dopamine and norepinephrine reuptake; available in both immediate-release and extended-release forms.
Dextroamphetamine (Dexedrine)
Contains only the d-isomer of amphetamine; may be tried if mixed salts cause unwanted side effects.
Atomoxetine (Strattera)
A non-stimulant option for ADHD that is not a controlled substance, making it suitable for patients with a history of substance abuse.
Prefer Amphetamine/Dextroamphetamine? We can find it.
MAO inhibitors
moderateContraindicated; can cause a potentially fatal hypertensive crisis. Must wait at least 14 days after stopping an MAOI.
Serotonergic drugs (SSRIs, SNRIs, triptans)
moderateRisk of serotonin syndrome when combined.
CYP2D6 inhibitors
moderateMay increase amphetamine blood levels and side effects.
Alkalinizing agents and antacids
moderateCan increase absorption of amphetamine.
Acidifying agents and vitamin C
moderateCan decrease absorption and reduce effectiveness.
Blood pressure medications
moderateAmphetamines may reduce the effectiveness of antihypertensives.
Amphetamine/Dextroamphetamine remains one of the most effective and commonly prescribed treatments for ADHD, but the ongoing shortage that started in October 2022 continues to make it challenging to find in stock. While supply has been improving following the DEA's production quota increase in late 2025, patients may still encounter difficulty at their local pharmacy—particularly for certain strengths and formulations. If you're struggling to locate your medication, Medfinder can help you search pharmacies near you that currently have it in stock. Talk to your prescriber about flexible dosing or alternative formulations if your usual dose is unavailable.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards